Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × eprenetapopt × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Myeloid 2 Lymphoid 1 Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Oxaliplatin 994 Fluorouracil 796 Capecitabine 755 Gemcitabine 644 Leucovorin 554 Irinotecan 535 Bevacizumab 502 Radiotherapy 455 Cisplatin 432 Drug Therapy 293 Cetuximab 278 Paclitaxel 226 Surgical Procedures, Operative 225 S 1 (combination) 214 pembrolizumab 204 Docetaxel 199 130-nm albumin-bound paclitaxel 195 Nivolumab 191 Radiosurgery 189 sintilimab 188 lenvatinib 179 Sorafenib 178 Folfox protocol 173 Albumin-Bound Paclitaxel 173 apatinib 169 camrelizumab 160 tislelizumab 158 Neoadjuvant Therapy 157 Blood Specimen Collection 152 durvalumab 147

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡